Registry for kidney cancer DNA and family history

Kidney Cancer DNA Registry

This study is collecting DNA samples and health information from people with kidney cancer and their families to better understand the disease and find ways to improve prevention and treatment.

Quick facts

• Study type: Observational
• Enrollment: 750 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Memorial Sloan Kettering Cancer Center (other)
• Locations: 7 sites (Basking Ridge, New Jersey and 6 other locations)
• Trial ID: NCT02087852 on ClinicalTrials.gov

What this trial studies

This registry aims to collect DNA samples and questionnaires from individuals diagnosed with kidney cancer, their family members, and healthy controls to enhance understanding of the disease. Participants will provide saliva samples for genetic analysis, complete a Kidney Cancer Questionnaire, and share family health histories. The data collected will help in developing improved methods for preventing, diagnosing, and treating renal cancer.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older who have been diagnosed with or suspected to have kidney cancer, as well as their blood relatives and healthy controls without a personal history of cancer.

Not a fit: Patients who are under 18 years old, do not speak English, or have a personal history of cancer (other than nonmelanoma skin cancer) may not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to better prevention and treatment strategies for kidney cancer, ultimately improving patient outcomes.

How similar studies have performed: Other studies utilizing genetic registries for cancer have shown promise in advancing understanding and treatment, suggesting this approach may yield valuable insights.

Eligibility criteria

Inclusion Criteria:

Kidney Cancer Case Cohort:

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must have a diagnosis or suspicion of kidney cancer

Family Member Cohort:

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required.

Control Cohort:

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND
* Must not be a blood relative of any cases or controls enrolled in this study

Exclusion Criteria:

* Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent

Where this trial is running

Basking Ridge, New Jersey and 6 other locations

• Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up) — Basking Ridge, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Monmouth (Consent and Follow up) — Middletown, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Bergen (Consent and Follow up ) — Montvale, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Commack (Consent and Follow-up) — Commack, New York, United States (RECRUITING)
• Memorial Sloan Kettering Westchester (Consent and Follow up) — Harrison, New York, United States (RECRUITING)
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (RECRUITING)
• Memorial Sloan Kettering Nassau (Consent and Follow-Up) — Uniondale, New York, United States (RECRUITING)

Study contacts

• Principal investigator: Jonathan Jonathan, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Jonathan Coleman, MD

Conditions: Renal Cancer, Questionnaire, DNA, saliva, kidney cancer, 13-218, high risk